Company / Cash & Equivalents
CHINA PHARMA HOLDINGS, INC. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$345.1K
FY2025
5-year range
$345.1K / $4.9M
FY2021-FY2025
Trend
-42.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $5M in FY2021 to $345,112 in FY2025.
Based on SEC 10-K filings.
$345,112 in FY2025 with a 5-year CAGR of -18.5%.
Declined from $1M to $345,112 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -44.6%
- 5-Year CAGR
- -18.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- CHINA PHARMA HOLDINGS, INC.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -18.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 42.5% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $345.1K | -42.5% |
| FY2024 | $600.0K | -57.9% |
| FY2023 | $1.4M | -29.9% |
| FY2022 | $2.0M | -58.2% |
| FY2021 | $4.9M | +407.4% |
| FY2020 | $957.7K | -10.9% |
| FY2019 | $1.1M | -47.1% |
| FY2018 | $2.0M | -23.8% |
| FY2017 | $2.7M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026